跳至主要内容
临床试验/NCT02726490
NCT02726490终止早期 1 期

Glyburide vs Glucovance in the Treatment of Gestational Diabetes

Texas Tech University Health Sciences Center, El Paso1 个研究点 分布在 1 个国家目标入组 7 人开始时间: 2016年7月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
早期 1 期
状态
终止
发起方
入组人数
7
试验地点
1
主要终点
efficacy of glyburide compared to glucovance

研究概览

简要总结

A randomized comparison of glyburide to glucovance (metformin -glyburide) in the management of diabetes in pregnancy.

详细描述

This study will be a randomized open label trial of glyburide compared to glucovance in the management of gestational diabetes. We hypothesize that glucovance will provide improved glycemic control and a lower failure rate with no increase in neonatal adverse outcomes. Sixty-seven patients will be randomized by computer to each arm of the study. Outcomes will be glycemic control, failure rate of the drug to achieve glycemic goals, and neonatal outcomes.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Gestational diabetes
  • Pregnancy > 12 weeks gestation
  • Ability to give consent

排除标准

  • Inability to consent to the study
  • Pre-existing diabetes
  • Glucose-6-phosphate dehydrogenase (G6PD) deficiency
  • Serum creatinine >1
  • Liver disease
  • Allergy to sulfa;
  • Allergy to glyburide;
  • Allergy to metformin;
  • Fetal anomalies

研究组 & 干预措施

Glyburide

Active Comparator
  • Patients will check and record blood glucose fasting and 1 hour after each meal each day. Patients will also keep a diary of all meals.
  • The starting dose of glyburide may be 2.5milligrams (mg) to 5mg every day(QD) or twice daily (BID) depending on the degree of hyperglycemia.
  • The dose of glyburide will be increased as needed to a maximum of 20mg /day.
  • Antenatal testing will be initiated at 28 weeks
  • Patients will receive monthly growth scans

干预措施: Glyburide (Drug)

Glucovance

Active Comparator
  • Patients will check and record blood glucose fasting and 1 hour after each meal each day. Patients will also keep a diary of all meals.
  • The starting dose of glucovance may be 1.25/250milligrams (mg) either once daily (QD) or twice a day (BID) increased to a maximum of 20mg/2000mg as needed.
  • Patients will receive monthly growth scans
  • Antenatal testing will be initiated at 28 weeks.

干预措施: Glucovance (Drug)

结局指标

主要结局

efficacy of glyburide compared to glucovance

时间窗: during the index pregnancy

failure rate of glyburide compared to glucovance in ability to achieve euglycemia

次要结局

  • maternal hypoglycemia(during the index pregnancy)
  • neonatal birthweight(at birth)
  • neonatal apgar scores(at birth)
  • neonatal admission to the newborn intensive care unit (NICU)(at birth or within the first 24 hours after birth)
  • neonatal hypoglycemia(up to 24 hours after delivery)

研究者

发起方
Texas Tech University Health Sciences Center, El Paso
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验